DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/z9w4l8/primary_immune) has announced the addition of the "Primary Immune Deficiency (PID)-Pipeline Insights" report to their offering.
Primary Immune Deficiency (PID) Pipeline Insights provides in-depth analysis of the pipeline assets across Primary Immune Deficiency (PID). The main objective of this report is to track competitor pipeline molecules, related research activities, technology, collaborations, and in-licensing and out-licensing deals. The Primary Immune Deficiency (PID) Report helps to identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage.
Primary Immune Deficiency (PID) Pipeline Insights Report covers the Primary Immune Deficiency (PID) pipeline molecules at various stages of development, like pre-registration phase, clinical phases (Phase III, Phase II & Phase I), pre-clinical and discovery phases. The Report also provides Primary Immune Deficiency (PID) related therapeutic assessments by molecule type, route of administration, monotherapy and combination products. The Report also highlights the discontinued and inactive projects in the pipeline for Primary Immune Deficiency (PID).
- The report provides a Primary Immune Deficiency (PID) Landscape across the globe
- The report provides drug profiles which include product description, MOA, licensors & collaborators, technology, development partner and chemical information
- Coverage of the Primary Immune Deficiency (PID) pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Primary Immune Deficiency (PID) and also provides company profiling
- Pipeline products coverage based on various stages of development from NDA filings to discovery
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type
For more information visit http://www.researchandmarkets.com/research/z9w4l8/primary_immune.